HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schillaci, O. Articles by Scopinaro, F. Search for Related Content PubMed PubMed Citation Articles by Schillaci, O. Articles by Scopinaro, F.

¹¹¹In-Pentetreotide Scintigraphy in the Detection of Insulinomas: Importance of SPECT Imaging

Nuclear Medicine, Department of Sciences and Biomedical Technologies, University of L'Aquila, L'Aquila
Department of Experimental Medicine and Pathology, University "La Sapienza", Rome, Italy

Correspondence: For correspondence or reprints contact: Orazio Schillaci, MD, Viale G. Mazzini 121, 00195 Rome, Italy.

ABSTRACT

The aim of this study was to determine whether the systematic use of SPECT can increase the reported low sensitivity of somatostatin receptor scintigraphy (SRS) in detecting insulinomas. Methods: Fourteen patients were evaluated. After ¹¹¹ln-pentetreotide injection (250 MBq intravenously), abdominal SPECT images were obtained at 4 h and multiple planar images were obtained at 4 and 24 h. MRI and CT were performed within 1 mo of SRS. Sixteen tumors were histologically verified after surgery in 14 patients. Results: SPECT revealed 14 lesions in 12 patients (sensitivity, 87.5%), both planar SRS and MRI revealed 7 tumors in 7 patients (sensitivity, 43.8%), and CT revealed only 5 lesions in 4 patients (sensitivity, 31.3%). Moreover, in 4 patients SPECT was the only examination with positive findings. Conclusion: SPECT at 4 h is mandatory for preoperative detection of insulinomas using SRS because the images are more sensitive than planar images and are superior to images from other conventional methods.

Key Words: somatostatin receptor scintigraphy • insulinomas • SPECT

This article has been cited by other articles:

				D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767. [Abstract] [Full Text] [PDF]

				O. Schillaci, A. Spanu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, N. Pisu, G. Madeddu, G. Delle Fave, and G. Madeddu Somatostatin Receptor Scintigraphy in Liver Metastasis Detection from Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., March 1, 2003; 44(3): 359 - 368. [Abstract] [Full Text] [PDF]